Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation

Howard R. Levin, Jonathan M. Chen, Mehmet C. Oz, Katharine A. Catanese, Henry Krum, Rochelle L. Goldsmith, Milton Packer, Eric A. Rose

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Left ventricular assist devices (LVADs) increasingly are being used as a bridge to transplantation. We studied changes in New York Heart Association class, mean arterial pressure, resting cardiac output, end-organ function, exercise oxygen consumption, and exercise cardiac output in 12 LVAD recipients. In addition, resting levels of neurohormonal factors were evaluated 4 to 16 weeks after implantation. Two of the 12 patients died of right heart failure and 1 of aspiration; all deaths occurred in the first 2 weeks after LVAD implantation. Of the other 9 patients, 8 improved to New York Heart Association class I and 1 to class II, all of whom were in class IV preoperatively. The 4 patients who underwent exercise testing achieved an exercise oxygen consumption of 15.0 ± 2.7 mL · kg-1 · min-1, which was paralleled by an increase in resting cardiac output from 3.07 ± 0.9 L · min-1 preoperatively to 5.66 ± 1.1 L · min-1 at 2 months, and mean arterial pressure from 60 ± 8 to 91 ± 10 mm Hg at 2 months, a benefit that was maintained for up to 10 months. End-organ function revealed comparable improvement at 2 months for both creatinine (1.68 ± 0.7 to 1.0 ± 0.19 mg · dL-1) and total bilirubin (1.37 ± 1.17 to 0.54 ± 0.26 mg · dL-1) levels. Levels of neurohormones were within normal limits. Adverse clinical events after the perioperative period were minimal, and no thromboembolic complications occurred. These data indicate that functional and physiologic recovery occurs during LVAD support, that adverse clinical and mechanical events occurring after the perioperative period are few and should not preclude hospital discharge in selected patients, and thus that LVADs can provide reliable, long-term support and should be evaluated for future use as outpatient therapy.

Original languageEnglish (US)
Pages (from-to)1515-1520
Number of pages6
JournalThe Annals of Thoracic Surgery
Volume58
Issue number5
DOIs
StatePublished - 1994

Fingerprint

Heart-Assist Devices
Outpatients
Transplantation
Cardiac Output
Exercise
Perioperative Period
Oxygen Consumption
Arterial Pressure
Therapeutics
Patient Rights
Bilirubin
Neurotransmitter Agents
Creatinine
Heart Failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Levin, H. R., Chen, J. M., Oz, M. C., Catanese, K. A., Krum, H., Goldsmith, R. L., ... Rose, E. A. (1994). Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. The Annals of Thoracic Surgery, 58(5), 1515-1520. https://doi.org/10.1016/0003-4975(94)91946-1

Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. / Levin, Howard R.; Chen, Jonathan M.; Oz, Mehmet C.; Catanese, Katharine A.; Krum, Henry; Goldsmith, Rochelle L.; Packer, Milton; Rose, Eric A.

In: The Annals of Thoracic Surgery, Vol. 58, No. 5, 1994, p. 1515-1520.

Research output: Contribution to journalArticle

Levin, HR, Chen, JM, Oz, MC, Catanese, KA, Krum, H, Goldsmith, RL, Packer, M & Rose, EA 1994, 'Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation', The Annals of Thoracic Surgery, vol. 58, no. 5, pp. 1515-1520. https://doi.org/10.1016/0003-4975(94)91946-1
Levin, Howard R. ; Chen, Jonathan M. ; Oz, Mehmet C. ; Catanese, Katharine A. ; Krum, Henry ; Goldsmith, Rochelle L. ; Packer, Milton ; Rose, Eric A. / Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. In: The Annals of Thoracic Surgery. 1994 ; Vol. 58, No. 5. pp. 1515-1520.
@article{bb621651b6044d028134d58229838186,
title = "Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation",
abstract = "Left ventricular assist devices (LVADs) increasingly are being used as a bridge to transplantation. We studied changes in New York Heart Association class, mean arterial pressure, resting cardiac output, end-organ function, exercise oxygen consumption, and exercise cardiac output in 12 LVAD recipients. In addition, resting levels of neurohormonal factors were evaluated 4 to 16 weeks after implantation. Two of the 12 patients died of right heart failure and 1 of aspiration; all deaths occurred in the first 2 weeks after LVAD implantation. Of the other 9 patients, 8 improved to New York Heart Association class I and 1 to class II, all of whom were in class IV preoperatively. The 4 patients who underwent exercise testing achieved an exercise oxygen consumption of 15.0 ± 2.7 mL · kg-1 · min-1, which was paralleled by an increase in resting cardiac output from 3.07 ± 0.9 L · min-1 preoperatively to 5.66 ± 1.1 L · min-1 at 2 months, and mean arterial pressure from 60 ± 8 to 91 ± 10 mm Hg at 2 months, a benefit that was maintained for up to 10 months. End-organ function revealed comparable improvement at 2 months for both creatinine (1.68 ± 0.7 to 1.0 ± 0.19 mg · dL-1) and total bilirubin (1.37 ± 1.17 to 0.54 ± 0.26 mg · dL-1) levels. Levels of neurohormones were within normal limits. Adverse clinical events after the perioperative period were minimal, and no thromboembolic complications occurred. These data indicate that functional and physiologic recovery occurs during LVAD support, that adverse clinical and mechanical events occurring after the perioperative period are few and should not preclude hospital discharge in selected patients, and thus that LVADs can provide reliable, long-term support and should be evaluated for future use as outpatient therapy.",
author = "Levin, {Howard R.} and Chen, {Jonathan M.} and Oz, {Mehmet C.} and Catanese, {Katharine A.} and Henry Krum and Goldsmith, {Rochelle L.} and Milton Packer and Rose, {Eric A.}",
year = "1994",
doi = "10.1016/0003-4975(94)91946-1",
language = "English (US)",
volume = "58",
pages = "1515--1520",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation

AU - Levin, Howard R.

AU - Chen, Jonathan M.

AU - Oz, Mehmet C.

AU - Catanese, Katharine A.

AU - Krum, Henry

AU - Goldsmith, Rochelle L.

AU - Packer, Milton

AU - Rose, Eric A.

PY - 1994

Y1 - 1994

N2 - Left ventricular assist devices (LVADs) increasingly are being used as a bridge to transplantation. We studied changes in New York Heart Association class, mean arterial pressure, resting cardiac output, end-organ function, exercise oxygen consumption, and exercise cardiac output in 12 LVAD recipients. In addition, resting levels of neurohormonal factors were evaluated 4 to 16 weeks after implantation. Two of the 12 patients died of right heart failure and 1 of aspiration; all deaths occurred in the first 2 weeks after LVAD implantation. Of the other 9 patients, 8 improved to New York Heart Association class I and 1 to class II, all of whom were in class IV preoperatively. The 4 patients who underwent exercise testing achieved an exercise oxygen consumption of 15.0 ± 2.7 mL · kg-1 · min-1, which was paralleled by an increase in resting cardiac output from 3.07 ± 0.9 L · min-1 preoperatively to 5.66 ± 1.1 L · min-1 at 2 months, and mean arterial pressure from 60 ± 8 to 91 ± 10 mm Hg at 2 months, a benefit that was maintained for up to 10 months. End-organ function revealed comparable improvement at 2 months for both creatinine (1.68 ± 0.7 to 1.0 ± 0.19 mg · dL-1) and total bilirubin (1.37 ± 1.17 to 0.54 ± 0.26 mg · dL-1) levels. Levels of neurohormones were within normal limits. Adverse clinical events after the perioperative period were minimal, and no thromboembolic complications occurred. These data indicate that functional and physiologic recovery occurs during LVAD support, that adverse clinical and mechanical events occurring after the perioperative period are few and should not preclude hospital discharge in selected patients, and thus that LVADs can provide reliable, long-term support and should be evaluated for future use as outpatient therapy.

AB - Left ventricular assist devices (LVADs) increasingly are being used as a bridge to transplantation. We studied changes in New York Heart Association class, mean arterial pressure, resting cardiac output, end-organ function, exercise oxygen consumption, and exercise cardiac output in 12 LVAD recipients. In addition, resting levels of neurohormonal factors were evaluated 4 to 16 weeks after implantation. Two of the 12 patients died of right heart failure and 1 of aspiration; all deaths occurred in the first 2 weeks after LVAD implantation. Of the other 9 patients, 8 improved to New York Heart Association class I and 1 to class II, all of whom were in class IV preoperatively. The 4 patients who underwent exercise testing achieved an exercise oxygen consumption of 15.0 ± 2.7 mL · kg-1 · min-1, which was paralleled by an increase in resting cardiac output from 3.07 ± 0.9 L · min-1 preoperatively to 5.66 ± 1.1 L · min-1 at 2 months, and mean arterial pressure from 60 ± 8 to 91 ± 10 mm Hg at 2 months, a benefit that was maintained for up to 10 months. End-organ function revealed comparable improvement at 2 months for both creatinine (1.68 ± 0.7 to 1.0 ± 0.19 mg · dL-1) and total bilirubin (1.37 ± 1.17 to 0.54 ± 0.26 mg · dL-1) levels. Levels of neurohormones were within normal limits. Adverse clinical events after the perioperative period were minimal, and no thromboembolic complications occurred. These data indicate that functional and physiologic recovery occurs during LVAD support, that adverse clinical and mechanical events occurring after the perioperative period are few and should not preclude hospital discharge in selected patients, and thus that LVADs can provide reliable, long-term support and should be evaluated for future use as outpatient therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028152833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028152833&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(94)91946-1

DO - 10.1016/0003-4975(94)91946-1

M3 - Article

C2 - 7979685

AN - SCOPUS:0028152833

VL - 58

SP - 1515

EP - 1520

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -